Enkang Pharmaceutical Technology (Guangzhou) Co., Ltd, a developer of DNA replication-initiation proteins (DRIPs)-targeted drugs, has reportedly raised “tens of millions” of renminbi in a Series B financing round. The round was solely led by CHER AMI Investment, with proceeds earmarked for new drug research and development.
EN002 Gel: First-in-Class Cancer Therapy
Enkang Pharma’s EN002 gel, a first-in-class DRIPs-targeted cancer therapy, has entered a Phase I/II clinical study in China, targeting non-melanoma skin cancer and precancerous lesions. This innovative approach aims to address significant unmet needs in oncology by targeting the initiation of DNA replication in cancer cells.
Partnership and Clinical Milestones
In 2014, Enkang Pharma partnered with US-based Eleison Pharmaceuticals Inc. to develop inhaled lipid cisplatin (ILC) for the treatment of lung cancer. The in-licensed product for Greater China received Phase III clinical trial approvals in the US in November 2021 and in China at the beginning of 2022. This partnership underscores Enkang’s commitment to advancing novel therapies through strategic collaborations.-Fineline Info & Tech
